Our Goal:

Develop a new class of compounds that selectively kill cancer cells by exploiting a difference in the microenvironments between cancer cells and healthy cells.

​Our distinctive approach provides broad applicability across different tumor types.

• We use unique medicinal chemistry to design non-toxic prodrugs that remain inactive until they enter cancer cells, where they are selectively activated to allow DNA binding and alkylation, leading to cell death

​​

• ​Our lead compound (CT-262) has completed preclinical development studies and is on the verge of entering clinical studies to provide proof of concept for this class of drugs

Investment Highlights

• Highly focused team with extensive pharmaceutical industry expertise

​​

• Patent protection: Exclusive, worldwide license agreement with TSRI for the CT-262 patent estate

 

• Potential near-term value inflection points

• New class of compounds leading to potential major advance in the treatment of cancer